RFC1 and colorectal cancer: Wettergren in “The use of folate transporters as biomarkers in colorectal cancer therapy” reported high expression of SLC46A1/PCFT, SLC19A1/RFC-1, and ABCC3/MRP3 was associated with longer 5-year disease-free survival (DFS) of patients with colorectal cancer (n = 363) treated with adjuvant 5-fluorouracil plus leucovorin (FLV), whereas there was no association between expression and DFS in untreated patients [53].